Keyphrases
5-HT1A Receptor
12%
6-hydroxydopamine (6-OHDA)
12%
Abnormal Involuntary Movements
100%
Adenylyl Cyclase
12%
Benserazide
12%
Bromocriptine
12%
Buspirone
12%
Chronic Treatment
12%
Cylinder Test
12%
D1-like Dopamine Receptor
12%
D2 Dopamine Receptor
100%
D2-like
12%
D3 Dopamine Receptor
100%
D3 Receptor
12%
D3 Receptor Antagonist
12%
Dopamine Agonist
12%
Dose Effect
12%
Dyskinesia
12%
Forelimb
12%
Forskolin
12%
Full Agonist
12%
HEK293 Cells
12%
In Vivo Efficacy
12%
Inhibition Assay
12%
Intrinsic Activity
25%
Involuntary Movement
12%
L-DOPA
100%
Levodopa-induced Dyskinesia
25%
Locomotor
12%
Maximum Intensity
12%
Movement Score
25%
Partial Agonist
25%
Patients with Parkinson's Disease
25%
Pharmaceutics
12%
Rotarod Task
12%
Selective Agonist
25%
Selective Antagonist
25%
SKF81297
12%
Spontaneous Locomotion
12%
Sprague-Dawley Rats
12%
Trifluoromethylphenylpiperazine (TFMPP)
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adenylate Cyclase
9%
Benserazide
9%
Bromocriptine
9%
Buspirone
9%
Dopamine 3 Receptor
27%
Dopamine Receptor
9%
Dopamine Receptor D2
100%
Dopamine Receptor Stimulating Agent
18%
Dyskinesia
100%
Forskolin
9%
Intrinsic Activity
18%
Levodopa
100%
Oxidopamine
9%
Parkinson's Disease
18%
Partial Agonist
18%
Receptor
18%
Receptor Antagonist
9%
Receptor Subtype
18%
Sprague Dawley Rat
9%